Literature DB >> 26013310

Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.

Ilker Sengul1, Seniz Akcay-Yalbuzdag1, Bugra Ince1, Altinay Goksel-Karatepe1, Taciser Kaya1.   

Abstract

AIM: To compare the Disease Activity Score with 28 joint (DAS28) using erythrocyte sedimentation rate (ESR) (DAS28-ESR) and DAS28 using C-reactive protein (CRP) (DAS28-CRP) with thresholds validated for DAS28-ESR in Turkish patients with rheumatoid arthritis.
METHOD: The DAS28 data of 112 patients with rheumatoid arthritis followed in a local outpatient clinic were used. First, the correlation between DAS28-CRP and DAS28-ESR and the correlation between their unique components ([0.36 × In (CRP + 1) + 0.96] and [0.70 × In (ESR)]) were analyzed. Second, a Bland-Altman plot was constructed for the evaluation of the level of agreement between DAS28-CRP and DAS28-ESR. Lastly, the agreement between these two methods was analyzed by κ coefficient.
RESULTS: Although there was a strong correlation between DAS28-CRP and DAS28-ESR, the correlation between their unique components was fair. Although more than 95% of the point data fall between the upper and lower bounds of the limit of agreement, the percentage error (46%) was higher than the acceptable proportion of 30%. The κ coefficient of agreement between DAS28- ESR and DAS28-CRP with validated thresholds for DAS28-ESR was 0.42, which was close to the lower boundary for moderate agreement.
CONCLUSION: The results of this study demonstrated that there is discordance between DAS28-ESR and DAS28-CRP with the validated thresholds for DAS28-ESR. Using the DAS28-CRP with threshold values validated for DAS28-ESR may lead to errors in the determination of disease activity and therefore may lead to errors in the management of patients with rheumatoid arthritis.
© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  C-reactive protein; DAS28; erythrocyte sedimentation rate; rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 26013310     DOI: 10.1111/1756-185X.12695

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  7 in total

1.  Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study.

Authors:  M Eissa; A El Shafey; M Hammad
Journal:  Clin Rheumatol       Date:  2017-05-22       Impact factor: 2.980

2.  Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort.

Authors:  Enriqueta Vallejo-Yagüe; Julia N Pfund; Theresa Burkard; Carole Clair; Raphael Micheroli; Burkhard Möller; Axel Finckh; Andrea M Burden
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

Review 3.  Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.

Authors:  Thang Dao; Ben Kirk; Steven Phu; Sara Vogrin; Gustavo Duque
Journal:  Calcif Tissue Int       Date:  2021-06-16       Impact factor: 4.333

4.  Radiographic changes in TMJ in relation to serology and disease activity in RA patients.

Authors:  Mostafa Mahmoud Youssef Mohamed; Mushira M Dahaba; Mary Medhat Farid; Adel Mahmoud Ali Elsayed
Journal:  Dentomaxillofac Radiol       Date:  2019-09-20       Impact factor: 2.419

5.  No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein: A cross-sectional study and theoretical consideration.

Authors:  Inger M J Hansen; Amir Emamifar; Rikke A Andreasen; Steen Antonsen
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 6.  Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.

Authors:  Philip G Conaghan; Eduardo Mysler; Yoshiya Tanaka; Barbara Da Silva-Tillmann; Tim Shaw; John Liu; Ryan Ferguson; Jeffrey V Enejosa; Stanley Cohen; Peter Nash; William Rigby; Gerd Burmester
Journal:  Drug Saf       Date:  2021-02-02       Impact factor: 5.606

7.  The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan.

Authors:  Khaldoon Alawneh; Abdel-Hameed Al-Mistarehi; Ali Qandeel; Ruba Jaber; Safwan Alomari; Khalid A Kheirallah
Journal:  Int J Clin Pract       Date:  2022-08-26       Impact factor: 3.149

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.